The cash influx has come from a mix of both old and new investors – reflecting the growing confidence in the potential of the device. The medical device company is best known for their magnetic blood filtration technology, a revolutionary new approach to targeting blood-borne diseases by magnetically filtering specific disease-causing components from the bloodstream. The device is being tested for the treatment of Malaria, Sepsis and Leukaemia.

As part of the latest funding round the private capital network 24Haymarket invested £632k with Marek Gumienny (Director of 24Haymarket) joining the board of MediSieve as a Non-Executive Director. This investment will contribute greatly to the further research and development of the company, providing a strong potential partner and source of capital to the company for the future.

Dr George Frodsham, founder and CEO of MediSieve explained, "This investment represents a watershed moment for MediSieve, and gives us the resources required to move forward with our product development and commercialisation over the coming years. We are very pleased to have found investors who will be actively involved in supporting the company as we grow, and who share our vision of a future where we can provide doctors with the ability to clean a patient's blood and treat a variety of blood-borne diseases. The best investors bring more than just funds, and I am very excited to have them join us on the journey. This is going to be a very exiting period of growth and development for MediSieve”.

Commenting on the investment, Marek Gumienny at 24Haymarket said “MediSieve is an excellent example of the type of businesses 24Haymarket is proud to back. We have an outstanding founder and entrepreneur in George Frodsham and potentially a global game changer in the treatment of such devastating diseases such as malaria and sepsis”.

As part of the team’s rapid period of growth, they have relocated operations to new offices and laboratories at the Imperial College London Translation & Innovation Hub (I-HUB). This suite of biotech-focused facilities and projects is part of the institution's facilities and support for science companies and their research.

The company says the move has hugely increased their research and development capability as on-site access to high-tech and well-equipped laboratories mean that they are working much quicker and cost-effectively. 

MediSieve’s vision for the future of healthcare is a world where doctors are able to target and remove infected cells, pathogens, toxins, or even viruses directly from a patient’s bloodstream. The ability to precisely extract unwanted disease-causing substances in this way would revolutionise the treatment of deadly blood-borne diseases, benefiting patients and clinicians around the world.

About Magnetic Blood Filtration 

MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.

About MediSieve

MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk